Study Details
Design, interventions, and primary outcomes
About This Study
The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand \[11C\]PBR28) in the lungs of patients living with PAH relative to age matched controls. If so, TSPO PET may be a useful technique to non-invasively monitor response to therapy. To do this, we will perform 2 \[11C\]PBR28 PET scans. The first will quantify the total \[11C\]PBR28 PET signal. This signal is a combination of the specific signal (VS) and the nonspecific signal (VND). The second scan will be performed following dosing with an unlabelled TSPO ligand. By directly measuring the total \[11C\]PBR28 signal (scan 1) and the nonspecific \[11C\]PBR28 signal (scan 2) we can therefore calculate the specific \[11C\]PBR28 signal, and hence the amount of TSPO in the lung.
Design
Interventions / Regimen
- Radiation: TSPO PET scan (11C-PBR28) — PET scan
Primary Outcomes
- The specific and non-specific fractions of the [11C]PBR28 signal in the lungs of healthy individuals and PAH patients. (2 years)
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-01
Completion: 2025-04
Sex: ALL
Volunteers: Not specified
Enrollment: 6 (ESTIMATED)
- Martin Wilkins (PRINCIPAL_INVESTIGATOR) - Imperial College London
- Radiation: TSPO PET scan (11C-PBR28) — PET scan